Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iganidipine
- Development stage
- Discontinued
- Lead developer
- Senju Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Iganidipine is a water-soluble, dihydropyridine-derivative calcium channel blocker developed by Senju Pharmaceutical. Unlike many other dihydropyridines, such as nifedipine or nicardipine, iganidipine exhibits high water solubility and superior stability under light, making it suitable for formulation as an ophthalmic solution. It acts as a calcium channel antagonist, promoting vasodilation and improving blood flow to the optic nerve head and retina. The drug was primarily investigated for the treatment of glaucoma and ocular hypertension. In 2006, ISTA Pharmaceuticals licensed the North American rights to the compound, but development was subsequently terminated.
- Other names
- iganidipine hydrochlorideiganidipine dihydrochloride
02
Targets
LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on iganidipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iganidipine.